Covalent inhibitors of the GTPase KRAS^G12C: a review of the patent literature

References

• Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in Cancer. Nucleic Acids Res. 2011;39:D945–D950.
   PubMed Web of Science ®Google Scholar
• Spencer-Smith R, O’Bryan JP. Direct inhibition of RAS: quest for the holy grail? Semin Cancer Biol. 2019;54:138–148.
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48:607–616.
   PubMed Web of Science ®Google Scholar
• Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7:596–609.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
   PubMed Web of Science ®Google Scholar
• Sun Q, Burke JP, Phan J, et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl. 2012;51:6140–6143.
   PubMed Web of Science ®Google Scholar
• Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A. 2012;109:5299–5304.
   PubMed Web of Science ®Google Scholar
• Shima F, Yoshikawa Y, Matsumoto S, et al. Discovery of small molecule Ras inhibitors that display antitumor activity by interfering with Ras. GTP-effector interaction. Enzymes. 2013;34(Pt. B):1–23.
   PubMedGoogle Scholar
• Ostrem JM, Peters U, Sos ML, et al. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–551.
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. Compositions and methods for treating cancer. 2013. (WO2103155223).
   Google Scholar
• Araxes Pharma LLC. Covalent inhibitors of KRAS G12C. 2014. (WO2014152588).
   Google Scholar
• Patricelli MP, Janes MR, Li L-S, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6:316–329.
   PubMed Web of Science ®Google Scholar
• Hansen R, Peters U, Babbar A, et al. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. Nat Struct Mol Biol. 2018;25:454–462.
   PubMed Web of Science ®Google Scholar
• Araxes Pharma LLC. Irreversible covalent inhibitors of the GTPase KRAS G12C. 2014. (WO2104143659).
   Google Scholar
• Peri F, Airoldi C, Colombo S, et al. Synthesis and biological evaluation of sugar‐derived ras inhibitors. ChemBioChem. 2005;6:1839–1848.
   PubMed Web of Science ®Google Scholar
• Airoldi C, Palmioli A, D’Urzo A, et al. Glucose-derived ras pathway inhibitors: evidence of ras–ligand binding and ras–GEF (Cdc25) interaction inhibition. ChemBioChem. 2007;8:1376–1379.
   PubMed Web of Science ®Google Scholar
• Taveras AG, Remiszewsky SW, Doll RJ, et al. Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg Med Chem. 1997;5:125–133.
   PubMed Web of Science ®Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C. 2015. (WO2015054572).
   Google Scholar
• Janes MR, Zhang J, Li L-S, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell. 2018;172:578–589.
   PubMed Web of Science ®Google Scholar
• Misale S, Fatherree JP, Cortez E, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res. 2019;25:796–807.
   PubMed Web of Science ®Google Scholar
• Araxes Pharma LLC. Substituted quinazoline compounds and methods of use thereof. 2016. (WO2016164675).
   Google Scholar
• Araxes Pharma LLC. Fused-tricyclic inhibitors of KRAS and methods of use thereof. 2016. (WO2016168540).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2016. (WO2016049524).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2017. (WO2017058915).
   Google Scholar
• Araxes Pharma LLC. Substituted quinazoline compounds and their use as inhibitors of the G12C mutant KRAS, HRAS and/or NRAS proteins. 2017. (WO2017015562).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2017. (WO2017058807).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2017. (WO2017058728).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2017. (WO2017058902).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2017. (WO2017058768).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2017. (WO2017058792).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2017. (WO2017058805).
   Google Scholar
• Araxes Pharma LLC. 2-Substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof. 2017. (WO20170087528).
   Google Scholar
• Araxes Pharma LLC. Inhibitors of KRAS G12C mutant proteins. 2018. (WO2018064510).
   Google Scholar
• Bhide RS, Cai ZW, Zhang YZ, et al. Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem. 2006;49:2143–2146.
   PubMed Web of Science ®Google Scholar
• Araxes Pharma LLC. Heterocyclic compounds as inhibitors of RAS and methods of use thereof. 2018. (WO2018068017).
   Google Scholar
• Araxes Pharma LLC. 1-(3-(6-(3-Hydroxynaphthalen-1-yl)benzofuran-2-yl)azetididin-1yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer. 2018. (WO2018140513).
   Google Scholar
• Araxes Pharma LLC. 1-(6-(3-Hydroxynaphthalen-1-yl)quinazolin-2-yl)azetididin-1yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C inhibitors for the treatment of cancer. 2018. (WO2018140514).
   Google Scholar
• Araxes Pharma LLC. Benzothiophene and benzothiazole compounds and methods of use thereof. 2018. (WO2018140599).
   Google Scholar
• Araxes Pharma LLC. Fused N-heterocyclic compounds and methods of use thereof. 2018 (WO2018140598).
   Google Scholar
• Araxes Pharma LLC. Fused bicyclic benzoheteroaromatic compounds and methods of use thereof. 2018. (WO2018140512).
   Google Scholar
• Araxes Pharma LLC. Fused hetero-hetero bicyclic compounds and methods of use thereof. 2018. (WO2018140600).
   Google Scholar
• Araxes Pharma LLC. Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS. 2018. (WO2018218069).
   Google Scholar
• Araxes Pharma LLC. Covalent inhibitors of KRAS. 2018. (WO2018218070).
   Google Scholar
• Araxes Pharma LLC. Compounds and methods of use thereof for treatment of cancer. 2018. (WO2018218071).
   Google Scholar
• Amgen INC. KRAS G12C inhibitors and methods of using the same. 2018. (WO2018119183).
   Google Scholar
• A Phase 1/2, study evaluating the safety, tolerability, PK, and efficacy of AMG 510 in subjects with solid tumors with a specific KRAS mutation. 2018 [cited 2019 Oct 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03600883
   Google Scholar
• Amgen INC. KRAS G12C inhibitors and methods of using the same. 2018. (WO2018217651).
   Google Scholar
• Amgen INC. Inhibitors of KRAS G12C and methods of using the same. 2019. (WO2019051291).
   Google Scholar
• Astellas Pharma INC. Quinazoline compound. (2018. (WO2018143315).
   Google Scholar
• AstraZeneca AB. Heteroaryl compounds that inhibit G12C mutant RAS proteins. 2018. (WO2018206539).
   Google Scholar
• AstraZeneca AB. Tetracyclic compounds as inhibitors of G12C mutant RAS proteins, for use as anti-cancer agents. 2019. (WO2019110751).
   Google Scholar
• Dana-Farber Cancer Institute INC. RAS inhibitors and use thereof. 2014. (WO2014160200).
   Google Scholar
• Lim SM, Westover KD, Ficarro SB, et al. Therapeutic targeting of oncogenic K‐ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014;53:199–204.
   PubMed Web of Science ®Google Scholar
• Hunter JC, Gurbani D, Ficarro SB, et al. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. PNAS. 2014;111:8895–8900.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Lu J, Hunter J, et al. Covalent guanosine mimetic inhibitors of G12C KRAS. ACS Med Chem Lett. 2017;8:61–66.
   PubMed Web of Science ®Google Scholar
• Medshine Discovery INC. Pyridone-pyrimidine derivative acting as KRASG12C mutant inhibitor. 2019. (WO2019141250).
   Google Scholar
• MRTX849 in patients with cancer having a KRAS G12C mutation. 2018 [cited 2019 Oct 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03785249
   Google Scholar
• Mirati Therapeutics INC. KRAS G12C inhibitors. 2017. (WO2017201161).
   Google Scholar
• Fell JB, Fischer JP, Baer BR, et al. Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity. ACS Med Chem Lett. 2018;9:1230–1234.
   PubMed Web of Science ®Google Scholar
• Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant-selective small molecule inhibitor, 2019 [cited 2019 Oct 2]. Available from: https://www.mirati.com/wp-content/uploads/2019/04/AACR_RAS_JHallin_03Apr2019_FINAL.pdf
   Google Scholar
• Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer. 2019 [cited 2019 Oct 2]. Available from: https://www.mirati.com/wp-content/uploads/2018/12/KRAS-Poster-AACR-RAS.pdf
   Google Scholar
• Structure-based drug discovery of a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer. 2018 [cited 2019 Oct 3]. Available from: https://www.mirati.com/wp-content/uploads/2018/08/ACS-2018_KRAS-Poster_FINAL4.pdf
   Google Scholar
• Mirati Therapeutics INC. KRAS G12C inhibitors. 2019. (WO2019099524).
   Google Scholar
• Pfizer INC. Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents. 2019. (WO2019150305).
   Google Scholar
• Pfizer INC. Tetrahydroquinazoline derivatives useful as anticancer agents. 2019. (WO2019155399).
   Google Scholar
• Caruso C, Rose S. Dueling KRASG12C inhibitors achieve responses. Cancer Discov. 2019. DOI:10.1158/2159-8290.CD-ND2019-012.
   Google Scholar
• Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217–223.
   PubMed Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:1–18.
   Google Scholar
• Shin Y, Jeong JW, Wurz RP, et al. Discovery of N‑(1-Acryloylazetidin-3-yl)-2-(1H‑indol-1-yl)acetamides as covalent inhibitors of KRASG12C. ACS Med Chem Lett. 2019;10:1302–1308.
   PubMed Web of Science ®Google Scholar
• Lopez P, Allen JR, Allen JG, et al. Optimization of quinazolinone-based covalent inhibitors of KRASG12C in the discovery of AMG 510. Abstracts of Papers, 258th ACS National Meeting & Exposition; 2019 August 25-29; San Diego, CA, United States. MEDI-0039.
   Google Scholar
• Molina-Arcas M, Moore C, Rana S, et al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci Transl Med. 2019;11:eaaw7999.
   PubMed Web of Science ®Google Scholar
• Lou K, Steri V, Ge AY, et al. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal. 2019;12:eaaw9450.
   PubMed Web of Science ®Google Scholar